Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876992 · ClinicalTrials.gov registry record · NA
Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
A NA study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01876992: Clinical Trial NA study, sponsored by Johns Hopkins University.
NCT01876992 is a NA study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01876992, a NA study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators know that metformin works at the level of the cells in the body by acting on a protein called Cyclic amine monophosphate- Response Binding Elements (CREB) binding protein or Constitutive Reverter of eIF2α Phosphorylation (CREP) Binding Protein (CBP). What the investigators do not know is how this process is affected when the dose of the metformin is increased or changed. Currently the same doses of metformin are often used in both children and adults, but it is possible that the dose of metformin should be based on age and weight. Understanding how CBP works could potentially help us to tailor metformin treatment individually for patients based on their age, weight and CBP response.
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01876992
The ClinicalTrials.gov registry entry for NCT01876992 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT01876992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01876992 about?
NCT01876992 is a clinical study titled "Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)". The investigators know that metformin works at the level of the cells in the body by acting on a protein called Cyclic amine monophosphate- Response Binding Elements (CREB) binding protein or Constitutive Reverter of eIF2α Phosphorylation (CREP) Binding Protein (CBP). What the investigators do not k...
What is the current status of trial NCT01876992?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2012-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01876992?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT01876992?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.